Xylanase mutant with improved thermal stability based on consensus sequence analysis and application of xylanase mutant

The Bacillus subtilis xylanase LC9 was modified through consensus site mutation technology, which improved its stability and activity at high temperature. The mutant N63I maintained high vitality under 50°C, significantly improving the hydrolysis capacity of xylan , solves the problem of poor thermal stability of proase and meets the needs of industrial applications.

CN118931880AInactive Publication Date: 2024-11-12NANJING TECH UNIV

Patent Information

Application Number
CN202411152042.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, the xylanase LC9 enzyme of Bacillus subtilis has low activity and poor thermal stability, which limits its application under high temperature conditions.

Method used

Through consensus site mutation technology, multiple xylanase mutants with improved thermal stability and enzyme activity were screened and obtained, specifically including at positions 17, 50, 63 and 101 of the amino acid sequence Mutations, mutants were constructed and expressed to improve the thermal stability and catalytic activity of the enzyme.

Benefits of technology

The mutant N63I remained 50% vital after being incubated at 50°C for 2 hours, which significantly improved the hydrolysis capacity and catalytic efficiency of the enzyme and met the needs of industrial applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931880A_ABST
    Figure CN118931880A_ABST
Patent Text Reader

Abstract

The invention relates to a xylanase mutant with remarkably improved thermal stability and application of the xylanase mutant, and belongs to the technical field of genetic engineering. The invention also relates to an expression vector and a host cell containing the mutant coding gene. An amino acid sequence (SEQ ID NO: 1) of alkali-resistant xylanase LC9 of bacillus subtilis is taken as a female parent, a series of xylanase mutants are obtained by adopting consensus site mutation and utilizing a single-point saturation mutation technology, and at least one site of the 63rd site, the 117th site and the 101th site is mutated. Compared with an original enzyme, the xylanase mutant shows remarkable thermal stability, the enzyme activity is improved, the construction method of the xylanase mutant is easy to operate and good in repeatability, and a foundation is laid for subsequent industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of genetic engineering and relates to a xylanase mutant with improved thermal stability and application thereof. Background Art

[0002] Xylan is the main component of hemicellulose in plant cell walls, accounting for about 15% to 35% of the dry weight of plant cells. The natural abundance of this polymer is second only to cellulose and is the main reserve of fixed carbon in the environment. Unlike cellulose, xylan is a complex polymer with a main chain composed of multiple xylanose groups connected by xylosidic bonds.

[0003] Xylan hydrolase is a general term for a class of glycoside hydrolases that can degrade xylan into oligoxylose and xylose. It is mainly responsible for breaking down the 1,4-β-D-glycosidic bonds within the xylan molecule and plays a key role in the degradation and conversion of plant biomass. In recent years, xylanases have been widely used in a variety of industrial applications, such as pulp and paper, feed, food, detergents and biofuel production. However, the industrial application of xylanases usually requires high temperature conditions, which may lead to enzyme denaturation and loss of catalytic activity.

[0004] In recent years, compared with traditional methods of improving enzyme catalytic performance, Wang et al. (Journal of Molecular Catalysis B: Enzymatic, 2022, 175: 106533) improved the catalytic activity of xylanase by integrating sequence and structural information. Using multiple sequence alignment and structural modeling tools, several conservative mutation sites of xylanase were identified. Subsequently, a series of mutants with significantly improved catalytic activity were obtained through site-directed mutagenesis and experimental verification. In order to improve the tolerance and catalytic efficiency of lipase from Bacillus subtilis, Zhang et al. (Biotechnology and Bioengineering, 2023, 120: 145-158) used a combination of computer simulation and directed evolution to identify and transform the amino acid residues around the active site of the enzyme, and finally found multiple mutants with significantly improved stability and catalytic activity at higher temperatures and organic solvents. Li et al. (ACS Synthetic Biology, 2024, 13: 453-467) modified glucose oxidase from Aspergillus niger, identified key dynamic regions through molecular dynamics simulation and structural analysis, and conducted saturation mutation and combinatorial mutation experiments on these regions. The modified enzyme not only had a significant improvement in catalytic efficiency, but also greatly enhanced its stability during long-term operation.

[0005] Although researchers at home and abroad have made significant progress in improving the catalytic activity of xylanase through protein engineering technology, there is still a lack of systematic theoretical understanding of the catalytic mechanism and dynamic behavior of xylanase, which limits the directional design and modification of xylanase. The sequence- and structure-based enzyme modification method not only provides a theoretical basis for protein engineering technology in the modification of xylanase to improve its catalytic activity, but also helps to reveal the special catalytic mechanism of this type of enzyme. Summary of the invention

[0006] In view of the shortcomings of the prior art Bacillus subtilis xylanase LC9, which has low enzyme activity and poor thermal stability, the present invention adopts single-point mutation and saturation mutation technology, transforms the thermal stability and enzyme activity of xylanase LC9 from Bacillus subtilis through consensus site mutation, screens key sites for molecular transformation, and obtains a series of xylanase mutants with improved thermal stability and enzyme activity.

[0007] The specific technical solutions of the present invention are as follows:

[0008] The xylanase mutant of the present invention is obtained by screening using the following method:

[0009] 1. Obtaining homologous sequences

[0010] The present invention uses the amino acid sequence of xylanase XynLC9 shown in SEQ ID NO: 1 as the parent, and uses BlastP (http: / / www.ncbi.nlm.nih.gov) to search the GenBank database for homologous sequences in the NCBI database. The first 225 homologous sequences are selected for the next step of screening according to sequence consistency.

[0011] 2. Design of consensus sequence

[0012] The above 225 homologous sequences were aligned using ClustalW software to generate MSA. The frequency of 20 amino acids and gap frequencies were then determined using a script. Positions occupied by residues (rather than gaps) in at least half of the sequences were included in the consensus sequence. The most common residues at these positions were collected to create a consensus sequence for the protein family. Using single-point saturation mutagenesis technology, a series of xylanase mutants were obtained based on the parent sequence.

[0013] The xylanase mutant of the present invention has amino acid mutations at positions 17, 50, 63, 101 and 136 based on the amino acid sequence of the xylanase shown in SEQ ID NO: 1.

[0014] Preferably, the mutant of the present invention is that the isoleucine at position 17 of the amino acid sequence shown in SEQ ID NO:1 is mutated to threonine, alanine, glutamic acid or aspartic acid, preferably threonine; and / or the asparagine at position 63 is mutated to methionine, valine or isoleucine, preferably isoleucine; and / or the lysine at position 101 is mutated to threonine, alanine, asparagine or aspartic acid, preferably threonine.

[0015] More preferably, the amino acid sequence of the mutant of the present invention is shown in any one of SEQ ID NO: 2 (N63I), SEQ ID NO: 3 (N63M), and SEQ ID NO: 4 (N63V).

[0016] Another object of the present invention is to provide a DNA molecule encoding the xylanase mutant of the present invention and an expression vector expressing the xylanase mutant.

[0017] The expression vector is a plasmid, a bacteriophage, a virus or a host cell. The host cell is a prokaryotic cell or a eukaryotic cell, preferably Escherichia coli, yeast, Bacillus, Lactobacillus, Aspergillus or Trichoderma.

[0018] Furthermore, the present invention also provides a method for constructing and expressing the mutant enzyme, preparing the mutant xylanase gene of the present invention by artificial synthesis or gene cloning, constructing an expression vector to obtain a recombinant plasmid, and transforming it into a host cell. Preferably, the host cell is Escherichia coli BL21.

[0019] Another object of the present invention is to provide the use of the xylanase mutant, DNA molecule or expression vector of the xylanase mutant in the biodegradation of xylan, which can be used to prepare xylobiose, xylotriose, xylotetraose and the like.

[0020] Specifically, the xylan includes beech wood xylan, soluble wheat arabinoxylan, birch wood xylan, and insoluble wheat arabinoxylan.

[0021] Beneficial Effects

[0022] The present invention designs a consensus sequence for xylanase XynLC9 to improve its thermal stability. The obtained mutant N63I has a substrate activity for beechwood xylan that is significantly higher than that of xylanase XynLC9.

[0023] In the prior art, after the xylanase XynLC9 was incubated at 30-70°C for 2 hours, its enzyme activity decreased significantly as the temperature increased. Through further research, the present invention found that the mutant N63I still maintained 50% activity after being incubated at 50°C for 2 hours, and the residual enzyme activity of the mutant N63I incubated at 30 to 50°C was higher than that of the original enzyme.

[0024] The experiment of using mutant N63I to hydrolyze corn cobs to prepare xylo-oligosaccharides showed that the enzymatic hydrolysis rate of mutant N63I was significantly higher than that of the original enzyme, and 2.8 mg / mL of reducing sugars were finally obtained, while xylanase XynLC9 only produced 1.5 mg / mL of reducing sugars. This result shows that mutant N63I has a higher hydrolysis ability than the original enzyme, showing superior properties of high catalytic efficiency and good thermal stability, which can fully meet the needs of industrial applications. Applying it to the catalytic reaction of xylan can significantly improve the production efficiency of xylo-oligosaccharides. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] The drawings constituting a part of this application are used to provide a further understanding of the present invention. The illustrative embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0026] Figure 1 is the relative enzyme activity of the mutant library.

[0027] Figure 2 Relative enzyme activity performance of different mutants in stability test

[0028] Figure 3 The results of the study on the optimal temperature for the original enzyme and mutants.

[0029] Figure 4 The results of the temperature stability study.

[0030] Figure 5 These are the results of the study on the optimal temperature of the original enzyme and mutants due to pH.

[0031] Figure 6 The results of analysis of the hydrolysis products of beechwood xylan by the original enzyme and mutant N63I.

[0032] Figure 7 The results of reducing sugar yield analysis of corncob xylan hydrolyzed by the original enzyme and mutant N63I. DETAILED DESCRIPTION

[0033] In order to further understand the content of the present invention, the present invention is described in detail in conjunction with the accompanying drawings and specific embodiments. However, these embodiments are only used to describe the present invention in detail and are not used to limit the scope of the present invention.

[0034] Example 1: Consensus sequence design of xylanase XynLC9 from Bacillus subtilis

[0035] In the NCBI database, the xylanase XynLC9 with the amino acid residue sequence of SEQ ID NO: 1 was used as the query sequence, and the GenBank database was searched using BlastP (http: / / www.ncbi.nlm.nih.gov) to retrieve its homologous sequence. 225 xylanase sequences from different species were selected, and their sequence identity covered 45%-85%. These sequences were multiple sequence aligned using ClustalW software, and the conserved regions and variable regions were identified based on the alignment results.

[0036] For its variable region, the frequency of occurrence of different amino acids at each site was counted. Amino acids with an occurrence frequency of more than 60% were selected as consensus residues, and their positions in the LC9 sequence were determined. Through this method, a total of 5 consensus residues were found, namely, positions 1, 17, 50, 63, 101, and 136. Specifically, the consensus residues are M1, I17, F50, N63, K101, and T136.

[0037] Example 2: Construction, expression and purification of XynLC9 mutants

[0038] The key amino acid residues determined in Example 1 were subjected to saturation mutation. The method disclosed by Bin Wu (Biotechnology for Biofuels, 2018, 11: 20) was used to construct a recombinant plasmid expressing the xylanase mutant N63. The sequence shown in SEQ ID NO: 2 was used as a template. The corresponding mutation primers designed as follows were used to amplify the site-directed mutation sequence from the whole plasmid. The primers used are as follows:

[0039]

[0040]

[0041] The PCR product was transformed into E. coli competent cells E. coli BL21 (DE3) and spread on LB agar plates containing 100 μg / ml kanamycin sulfate and cultured at 37°C for 14-16 hours. The mutation results were verified by sequence determination (completed by Nanjing TSINGKE Biological Company). The construction of the mutant took the N63 site as an example, using conventional PCR technology, and using the xylanase XynLC9 expression vector as a template to amplify the whole plasmid to introduce mutations. The resulting N63 mutant library was successfully constructed by sequencing verification.

[0042] The N63 mutant and the original enzyme XynLC9 constructed above were inoculated into 50 mL of LB liquid medium containing 100 μg / mL kanamycin sulfate, and cultured overnight at 180 rpm / min and 37°C. The seed solution of the overnight culture was inoculated into 50 mL of fresh LB liquid medium at a 2% inoculum, and cultured at 180 rpm / min and 37°C until OD 600 When the concentration was between 0.6 and 1.0, the mixture was taken out and cooled in an ice water bath for 5 min, and the inducer IPTG (final concentration 0.1 mmol L -1 ), and induced expression at 25°C for 24 h.

[0043] Subsequently, the cells were harvested, centrifuged at 12000 rpm / min for 20 min, the supernatant was discarded, and the cells were lysed in lysis buffer (50 mmol / l Na 2 PO 4 / NaH 2 PO 4 , pH 7.0), centrifuged at 12000 rpm for 20 min, discarded the supernatant, resuspended again with buffer, and disrupted by ultrasound. The enzyme activity of the resulting supernatant was determined, and mutants with higher enzyme activity than XynLC9 were selected. Then, these mutants and XynLC9 were purified at one time using HisTrap FF columns. The apparent molecular weight and homogeneity of the purified enzyme were determined on a 12% SDS-PAGE gel.

[0044] Referring to the above method, mutation libraries of I17, F50, K101, and T136 were constructed, and the corresponding mutants were purified.

[0045] Example 3: Screening of LC9 mutants

[0046] A reaction mixture was prepared by mixing 1 mL of 1% (w / v) beechwood xylan in a 20 mM sodium phosphate buffer having a pH value of 7.0 and 500 μL of an appropriately diluted xylanase sample, incubated at 60°C for 5 min, adding 0.5 mL of an appropriately diluted protease solution, and reacting in a 60°C water bath shaker for 15 min, adding 3 mL of dinitrosalicylic acid reagent (DNS), reacting in a boiling water bath for 5 min, and then rapidly cooling to room temperature. The absorbance value at a wavelength of 540 nm was measured using the inactivated enzyme reaction solution as a control.

[0047] The enzyme activity unit of xylanase is defined as the amount of enzyme required to produce 1 mmol of reducing sugar from the substrate per minute at 60°C and pH 7.0.

[0048] Specific enzyme activity X = (reducing sugar content / 150 / 15) / n

[0049] in:

[0050] X——Specific enzyme activity, U / mg

[0051] 150 - Convert reducing sugars from milligrams to micromoles

[0052] 15 – Reaction time

[0053] n——reactive protein content, mg

[0054] The highest enzyme activity was taken as 100%, and the relative enzyme activities were calculated in sequence.

[0055] The mutants obtained in Example 2 were tested for enzyme activity using the above method. The relative enzyme activity of each mutant was as follows: Figure 1 shown. Figure 1 The results showed that the enzyme activities of F50R, N63M, N63V and N63I mutants were improved compared with the original enzyme LC9, while the enzyme activities of the other mutants were significantly reduced. Therefore, the F50R, N63M, N63V and N63I mutants with enzyme activities retaining more than 90% of the control were selected for stability experiments.

[0056] After incubating the enzyme solutions of xylanase and xylanase mutants at 50°C for 30 minutes, the relative enzyme activities were determined according to the above method. Figure 2 As shown in the figure, specifically, the N63I, N63M and N63V mutants still maintained high relative activities after incubation at 50°C for 30 minutes, reaching about 10%, 5% and 4%, respectively, while the relative activities of the remaining mutants were significantly lower. This indicates that the N63I, N63M and N63V mutants excel in stability and may have high application potential.

[0057] Example 4: Analysis of enzymatic properties of enzyme mutants

[0058] 1. Optimum temperature and optimum pH

[0059] In order to determine the optimal temperature of the mutants and the original enzyme, the enzyme solutions of the mutants F50R, N63I, N63M, N63V and the original enzyme LC9 obtained in Example 3 were diluted to a certain concentration and 0.5 ml was added to a test tube containing 1.0 mL of beechwood xylan substrate, and reacted at 50°C, 55°C, 60°C, 65°C, and 70°C for 15 min. After the reaction, 3 mL of DNS solution was added and boiled for 5 min to determine the enzyme activity. The highest enzyme activity was taken as 100%, and the relative enzyme activity was calculated in turn, and a curve of enzyme activity changing with temperature was drawn. The results are shown in FIG. Figure 3As shown, the optimum temperature of the original enzyme LC9 and the mutants N63I, N63M, and N63V is 60°C. In order to determine the temperature stability of the mutants and the original enzyme, the enzyme solutions of the original enzyme and the mutants were placed in a 50°C water bath for 2 hours, and then the enzyme activity changes were determined according to the method in Example 3. The highest enzyme activity was taken as 100%, and the relative enzyme activity was calculated in turn, and the change curve of the enzyme activity over time was plotted.

[0060] like Figure 4 As shown, all enzymes showed the same relative activity at the initial time point. As time went on, the activity of the original enzyme decreased rapidly, and by 10 minutes it had dropped to about 20%, and then it was almost completely lost, showing poor stability. In contrast, although the activity of mutants N63M and N63V decreased slightly slower than that of the original enzyme, they still decreased significantly within 20 minutes, with N63V performing slightly better than N63M. The performance of mutant N63I was the most outstanding, with the slowest activity decline, especially maintaining a high activity between 10 and 20 minutes, and still maintaining a certain level of activity at 60 minutes, showing excellent stability.

[0061] In order to determine the optimal pH of the mutant and the original enzyme, the enzyme solutions of the original enzyme XynLC9 and the mutants N63I, N63M, and N63V were placed in NaOH solutions with different pH values. 2 HPO 4 -KH 2 PO 4 The solution was incubated in a 50°C water bath for 2 h, and then the enzyme activity was measured according to the method in Example 3. The highest enzyme activity was taken as 100%, and the relative enzyme activity was calculated in turn, and a curve of enzyme activity changing with time was drawn. The results are shown in FIG. Figure 5 As shown, the optimal pH of the original enzyme LC9 and mutants N63I, N63M, and N63V is 7.0.

[0062] 2. Analysis of hydrolysis products of the original enzyme LC9 and mutants N63I, N63M, and N63V

[0063] The enzyme solutions of the original enzyme XynLC9 and mutants N63I, N63M, and N63V were used to hydrolyze beechwood xylan as substrate. First, the diluted enzyme solution was mixed with the substrate in a 1:1 ratio, and the enzyme solution was inactivated by boiling after reacting at 45°C for 1 hour, and then centrifuged at 12000rpm for 10 minutes, the supernatant was collected and pre-cooled ethanol was added overnight to precipitate impurities, and the hydrolyzate was obtained by dissolving it in distilled water after drying. In the thin layer chromatography test, the thin layer plate was activated in a 120°C oven for 1 hour and then used for standby. The developing agent was mixed in a ratio of n-butanol: acetic acid: water = 3:2:1, and the standard and sample were spotted separately and developed twice, each time for 1.5 hours. When developing color, concentrated sulfuric acid and ethanol were mixed in a 1:9 ratio and sprayed on the surface of the thin layer plate. After color development in a 120°C oven for 5 minutes, the hydrolysis product was judged according to the standard.

[0064] like Figure 6 As shown, the hydrolysis products of beechwood xylan substrate by xylanase XynLC9 and the best mutants N63I, N63M, and N63V are mainly xylobiose and xylotriose.

[0065] Example 5: Application of enzyme mutants in hydrolyzing corncobs to produce xylo-oligosaccharides

[0066] The crude enzyme solution of mutant N63I obtained by screening in Example 3 was used to hydrolyze corn cobs to prepare xylo-oligosaccharides. The specific steps are as follows: 0.5 g of corn cob xylan extracted by alkali treatment was added with 20 ml of pure water, and the reaction was carried out at 50°C and 160 rpm for 72 hours. A small amount of supernatant sample was taken every 6 hours, and the reducing sugar content produced was determined by DNS method.

[0067] The time curves of the original enzyme XynLC9 and mutant N63I in degrading corn cobs to produce reducing sugars are shown in Figure 2. Figure 7 As shown. The reducing sugar production increased rapidly within 24 hours after the start of enzymatic hydrolysis, and the production increase trend slowed down after 24 hours. The mutant N63I finally obtained 2.8 mg / mL reducing sugar, which is about 1.8 times the reducing sugar production of the original enzyme XynLC9 (1.5 mg / mL). This result shows that the mutant N63I has a higher hydrolysis ability than the original enzyme XynLC9, which will help reduce the enzyme dosage for xylo-oligosaccharide production, thereby reducing the overall production cost.

[0068] The present invention and its embodiments are described schematically above, and the description is not restrictive. The drawings show only one embodiment of the present invention, and the actual structure is not limited thereto. Therefore, if a person skilled in the art is inspired by it and designs a structural method and an embodiment similar to the technical solution without creativity without departing from the purpose of the invention, they shall all fall within the protection scope of the present invention.

Claims

1. A xylanase mutant, characterized in that The mutant is a mutant in which at least one of the 17th, 50th, 63rd, 101st and 136th amino acid positions of the amino acid sequence shown in SEQ ID NO: 1 is mutated.

2. The xylanase mutant according to claim 1, characterized in that The mutant is an amino acid sequence shown in SEQ ID NO: 1 in which the isoleucine at position 17 is mutated to threonine, alanine, glutamic acid or aspartic acid; and / or the asparagine at position 63 is mutated to methionine, valine or isoleucine; and / or the lysine at position 101 is mutated to threonine, alanine, asparagine or aspartic acid.

3. The xylanase mutant according to claim 2, characterized in that The mutant is that the isoleucine at position 17 of the amino acid sequence shown in SEQ ID NO: 1 is mutated to threonine; and / or the asparagine at position 63 is mutated to methionine, valine or isoleucine; and / or the lysine at position 101 is mutated to threonine.

4. A DNA molecule, characterized in that The DNA molecule encodes the xylanase mutant according to any one of claims 1-3.

5. An expression vector for a xylanase mutant, characterized in that Expressing the xylanase mutant according to any one of claims 1 to 3.

6. The expression vector according to claim 5, characterized in that Containing the DNA molecule according to claim 5.

7. The expression vector according to claim 5, characterized in that The expression vector is a plasmid, a phage, a virus or a host cell.

8. The expression vector according to claim 7, characterized in that The host cell is a prokaryotic cell or a eukaryotic cell.

9. The expression vector according to claim 8, characterized in that The host cell is selected from Escherichia coli, yeast, Bacillus, Lactobacillus, Aspergillus or Trichoderma.

10. Use of the xylanase mutant according to any one of claims 1 to 3, the DNA molecule according to claim 4 or the expression vector of the xylanase mutant according to any one of claims 5 to 9 in xylan biodegradation.

Citation Information

Patent Citations

  • Expansion protein and xylanase fusion protein, coding gene and applications thereof

    CN108570107A

  • Class of fused xylanase mutants with high specific activity and application thereof

    CN112300291A

  • High-specific-enzyme-activity xylanase mutant and application thereof

    CN112322604A

  • Xylanase GH11-xyllanase mutant and application of xylanase GH11-xyllanase mutant

    CN112662648A

  • Xylanase mutant with thermal stability

    CN117511914A

Cited By

  • Novel adeno-associated virus variant library for gene and cell therapy as well as construction and application of novel adeno-associated virus variant library

    CN119570747A